According to Figure 3 and Table 3, the results of the network meta-analysis for different safety events are described as follows:
In patients with HR+/HER2- advanced breast cancer, Dato-DXd and SG showed a significant improvement in ORR and a trend toward improved PFS compared to chemotherapy. The probability ranking results indicated that for both ORR and PFS, Dato-DXd ranked first, followed by SG. In the analysis of OS, the probability ranking order was SG, chemotherapy, and Dato-DXd.
In advanced TNBC, the ranking for ORR and OS was SG, SKB264, and chemotherapy; for PFS, the ranking was SKB264, SG, and chemotherapy.
